Jonas Rieth
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Journal: Nature communications
Published: June 14, 2023
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Journal: Nature communications
Published: July 29, 2022
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Journal: Nature
Published: August 17, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
Journal: Cancer discovery
Published: February 12, 2021
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.
Journal: Science translational medicine
Published: November 17, 2020
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.
Journal: Nature immunology
Published: June 10, 2020
Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
Journal: International immunopharmacology
Published: September 18, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026